Mainz Biomed Past Earnings Performance
Past criteria checks 0/6
Mainz Biomed's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 16.2% per year.
Key information
-32.6%
Earnings growth rate
-21.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 16.2% |
| Return on equity | n/a |
| Net Margin | -2,453.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mainz Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -23 | 15 | 7 |
| 31 Mar 24 | 1 | -25 | 17 | 9 |
| 31 Dec 23 | 1 | -26 | 18 | 10 |
| 30 Sep 23 | 1 | -29 | 19 | 10 |
| 30 Jun 23 | 1 | -29 | 20 | 9 |
| 31 Mar 23 | 1 | -27 | 22 | 6 |
| 31 Dec 22 | 1 | -26 | 22 | 5 |
| 30 Sep 22 | 0 | -24 | 21 | 2 |
| 30 Jun 22 | 0 | -24 | 21 | 1 |
| 31 Mar 22 | 1 | -17 | 15 | 1 |
| 31 Dec 21 | 1 | -12 | 9 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
Quality Earnings: 4TO is currently unprofitable.
Growing Profit Margin: 4TO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4TO is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare 4TO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4TO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 4TO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.